We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Moves -0.41%: What You Should Know
Read MoreHide Full Article
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $550.01, marking a -0.41% move from the previous day. This change was narrower than the S&P 500's 1.47% loss on the day. Elsewhere, the Dow lost 1.14%, while the tech-heavy Nasdaq lost 1.57%.
Coming into today, shares of the drugmaker had lost 0.29% in the past month. In that same time, the Medical sector lost 2.14%, while the S&P 500 lost 1.43%.
Investors will be hoping for strength from Eli Lilly as it approaches its next earnings release. The company is expected to report EPS of $2.88, up 45.45% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.92 billion, up 28.53% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $9.84 per share and revenue of $33.62 billion. These totals would mark changes of +23.93% and +17.79%, respectively, from last year.
Any recent changes to analyst estimates for Eli Lilly should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.04% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Eli Lilly has a Forward P/E ratio of 56.16 right now. Its industry sports an average Forward P/E of 14.72, so we one might conclude that Eli Lilly is trading at a premium comparatively.
Investors should also note that LLY has a PEG ratio of 2.27 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. LLY's industry had an average PEG ratio of 1.76 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 200, which puts it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Stock Moves -0.41%: What You Should Know
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $550.01, marking a -0.41% move from the previous day. This change was narrower than the S&P 500's 1.47% loss on the day. Elsewhere, the Dow lost 1.14%, while the tech-heavy Nasdaq lost 1.57%.
Coming into today, shares of the drugmaker had lost 0.29% in the past month. In that same time, the Medical sector lost 2.14%, while the S&P 500 lost 1.43%.
Investors will be hoping for strength from Eli Lilly as it approaches its next earnings release. The company is expected to report EPS of $2.88, up 45.45% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $8.92 billion, up 28.53% from the year-ago period.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $9.84 per share and revenue of $33.62 billion. These totals would mark changes of +23.93% and +17.79%, respectively, from last year.
Any recent changes to analyst estimates for Eli Lilly should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 0.04% higher within the past month. Eli Lilly is currently sporting a Zacks Rank of #3 (Hold).
Valuation is also important, so investors should note that Eli Lilly has a Forward P/E ratio of 56.16 right now. Its industry sports an average Forward P/E of 14.72, so we one might conclude that Eli Lilly is trading at a premium comparatively.
Investors should also note that LLY has a PEG ratio of 2.27 right now. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. LLY's industry had an average PEG ratio of 1.76 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 200, which puts it in the bottom 21% of all 250+ industries.
The Zacks Industry Rank includes is listed in order from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.